Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Grants and Contracts Details

StatusFinished
Effective start/end date8/10/21 → 10/19/22

Funding

  • CRISPR Therapeutics AG: $28,617.00